Teva announced that Adasuve (loxapine) inhalation powder is now available for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

The exact mechanism of action of loxapine, a typical antipsychotic, in the treatment of agitation associated with schizophrenia is unknown. However, its efficacy could be mediated through a combination of antagonism of central dopamine D2 and serotonin 5-HT2A receptors.

RELATED: Psychiatric Disorders Resource Center

Adasuve can cause bronchospasm that can potentially lead to respiratory distress and respiratory arrest. Due to its risk of bronchospasm, Adasuve is only available through a restricted program called the Adasuve REMS Program.  

Adasuve inhalation powder is available in a 10mg dosage strength as a single-use, disposable inhaler in 5-unit cartons.

For more information call (800) 292-4283 or visit